RBC Maintains Outperform for ONC BeOne Medicines Ltd. Feb 2026

RBC Capital kept Outperform for BeOne Medicines Ltd. (ONC) and raised the price target to $425. The ONC analyst rating remains Outperform after the firm confirmed coverage on February 26, 2026. This move updated the price target from prior levels while keeping the rating unchanged. Investors should note the firm signaled confidence in BeOne’s fundamentals and pipeline.